Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.61 |
| ▸ | CCNE2 | O96020 | 8/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 8/20 | 0.55 |
| ▸ | CDK2 | P24941 | 8/20 | 0.55 |
| ▸ | CDK1 | P06493 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27249598 | 1.00 | CTSL (0.61) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL30747777 | 0.94 | CTSL (0.58) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL27249658 | 0.94 | CTSL (0.58) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL30747726 | 0.93 | CTSL (0.60) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL27249677 | 0.93 | CTSL (0.60) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL30747819 | 0.93 | CTSL (0.62) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL27249494 | 0.93 | CTSL (0.62) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL30747798 | 0.83 | CCNE2 (0.77) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL27249486 | 0.83 | CCNE2 (0.77) | CTSLCCNE2CCNE1CDK2CDK1 | |
| SCHEMBL27249493 | 0.80 | CTSL (0.64) | CTSLCCNE2CCNE1CDK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215032-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-07-03 | — | — | US | disclosed |
| EP-4554678-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-05-21 | — | — | EP | disclosed |
| WO-2024013205-A9 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2025-04-10 | — | — | WO | disclosed |
| WO-2024013205-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250215032-A1 | PHOSPHORYLPURINONE COMPOUNDS FOR THE TREATMENT OF CANCER | CDK1, UPP1, CDK10 | CTSL 2377/4885CCNE2 653/4885CCNE1 125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.